CRA was retained by a pharmaceutical company to assist in settlement negotiations with a potential generic competitor. As part of this project, CRA prepared a flexible valuation model to estimate the expected profits from the perspective of the generic competitor under various assumptions. CRA also prepared a decision probability tree analysis to address issues related to litigation risk, acceptable date of generic entry and the impact of an authorized generic.
Patent damages: Recent trends in Rule 702 decisions
Rule 702 decision trends are based on our review of available US district court decisions concerning damages experts in patent infringement matters that have...